Hsiao Amber, Desai Sachin N, Mogasale Vittal, Excler Jean-Louis, Digilio Laura
Development and Delivery Unit, International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Seoul, 08826, Republic of Korea.
Department of Policy and Economic Research, International Vaccine Institute, Seoul, Republic of Korea.
Bull World Health Organ. 2017 Apr 1;95(4):303-312. doi: 10.2471/BLT.16.175166. Epub 2017 Feb 21.
Improving water and sanitation is the preferred choice for cholera control in the long-term. Nevertheless, vaccination is an available tool that has been shown to be a cost-effective option for cholera prevention in endemic countries or during outbreaks. In 2011 the first low-cost oral cholera vaccine for international use was given prequalification by the World Health Organization (WHO). To increase and prioritize use of the vaccine, WHO created a global stockpile in 2013 from which countries may request oral cholera vaccine for reactive campaigns. WHO has issued specific guidelines for applying for the vaccine, which was previously in short supply (despite prequalification for a second oral vaccine in 2015). The addition of a third WHO-prequalified oral cholera vaccine in 2016 is expected to increase the global stockpile considerably and alleviate supply issues. However, prioritization and best use of the vaccine (e.g. how, when and where to use) will remain challenges. We describe 12 past oral cholera vaccine campaigns, conducted in settings with varying burdens of cholera. These case studies illustrate three key challenges faced in the use of the oral cholera vaccines: regulatory hurdles, cold chain logistics and vaccine coverage and uptake. To pave the way for the introduction of current and future oral cholera vaccines, we discuss operational challenges and make recommendations for future research with respect to each of these challenges.
从长远来看,改善水和环境卫生是控制霍乱的首选方案。然而,疫苗接种是一种可用工具,已证明在霍乱流行国家或疫情期间是预防霍乱的具有成本效益的选择。2011年,首款用于国际的低成本口服霍乱疫苗获得世界卫生组织(WHO)的预认证。为了增加疫苗的使用并确定其优先顺序,WHO于2013年建立了一个全球储备库,各国可从中申请口服霍乱疫苗用于反应性接种活动。WHO已发布了申请该疫苗的具体指南,此前该疫苗供应短缺(尽管2015年第二种口服疫苗也获得了预认证)。预计2016年第三种获得WHO预认证的口服霍乱疫苗的加入将大幅增加全球储备并缓解供应问题。然而,确定疫苗的优先顺序以及最佳使用方式(例如如何、何时以及何地使用)仍将是挑战。我们描述了在霍乱负担各不相同的环境中开展的12次既往口服霍乱疫苗接种活动。这些案例研究说明了口服霍乱疫苗使用中面临的三个关键挑战:监管障碍、冷链物流以及疫苗覆盖率和接种率。为引入当前及未来的口服霍乱疫苗铺平道路,我们讨论了操作方面的挑战,并针对每个挑战提出了未来研究的建议。